company background image
DBV

DBV TechnologiesENXTPA:DBV Stock Report

Market Cap

€291.4m

7D

0.3%

1Y

28.3%

Updated

30 Nov, 2021

Data

Company Financials +
DBV fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

DBV Stock Overview

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.

DBV Technologies Competitors

Genmab

CPSE:GMAB

kr.166.8b

argenx

ENXTBR:ARGX

€12.7b

Recordati Industria Chimica e Farmaceutica

BIT:REC

€11.4b

Evotec

XTRA:EVT

€7.3b

Price History & Performance

Summary of all time highs, changes and price drops for DBV Technologies
Historical stock prices
Current Share Price€5.30
52 Week High€13.69
52 Week Low€3.91
Beta2.2
1 Month Change-7.89%
3 Month Change-43.91%
1 Year Change28.32%
3 Year Change-80.19%
5 Year Change-92.21%
Change since IPO-40.96%

Recent News & Updates

Oct 20
Will DBV Technologies (EPA:DBV) Spend Its Cash Wisely?

Will DBV Technologies (EPA:DBV) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

DBVFR BiotechsFR Market
7D0.3%14.3%-3.5%
1Y28.3%5.2%21.5%

Return vs Industry: DBV exceeded the French Biotechs industry which returned 7.2% over the past year.

Return vs Market: DBV exceeded the French Market which returned 23.7% over the past year.

Price Volatility

Is DBV's price volatile compared to industry and market?
DBV volatility
DBV Average Weekly Movement10.6%
Biotechs Industry Average Movement6.8%
Market Average Movement4.6%
10% most volatile stocks in FR Market9.3%
10% least volatile stocks in FR Market2.6%

Stable Share Price: DBV is more volatile than 90% of French stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: DBV's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
200292Daniel Tasséhttps://www.dbv-technologies.com

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordetella pertussis.

DBV Technologies Fundamentals Summary

How do DBV Technologies's earnings and revenue compare to its market cap?
DBV fundamental statistics
Market CapUS$328.42m
Earnings (TTM)-US$123.62m
Revenue (TTM)US$1.56m

210.1x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DBV income statement (TTM)
RevenueUS$1.56m
Cost of RevenueUS$0
Gross ProfitUS$1.56m
ExpensesUS$125.18m
Earnings-US$123.62m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.25
Gross Margin100.00%
Net Profit Margin-7,904.09%
Debt/Equity Ratio0.6%

How did DBV perform over the long term?

See historical performance and comparison

Valuation

Is DBV Technologies undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: DBV (€5.3) is trading below our estimate of fair value (€53.83)

Significantly Below Fair Value: DBV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: DBV is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: DBV is unprofitable, so we can't compare its PE Ratio to the French market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DBV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DBV is good value based on its PB Ratio (2.8x) compared to the FR Biotechs industry average (4x).


Future Growth

How is DBV Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

48.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DBV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.3%).

Earnings vs Market: DBV is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: DBV's is expected to become profitable in the next 3 years.

Revenue vs Market: DBV's revenue (96% per year) is forecast to grow faster than the French market (6.6% per year).

High Growth Revenue: DBV's revenue (96% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if DBV's Return on Equity is forecast to be high in 3 years time


Past Performance

How has DBV Technologies performed over the past 5 years?

-0.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DBV is currently unprofitable.

Growing Profit Margin: DBV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DBV is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.

Accelerating Growth: Unable to compare DBV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DBV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (50.7%).


Return on Equity

High ROE: DBV has a negative Return on Equity (-105.76%), as it is currently unprofitable.


Financial Health

How is DBV Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: DBV's short term assets ($110.1M) exceed its short term liabilities ($33.8M).

Long Term Liabilities: DBV's short term assets ($110.1M) exceed its long term liabilities ($20.2M).


Debt to Equity History and Analysis

Debt Level: DBV has more cash than its total debt.

Reducing Debt: DBV's debt to equity ratio has reduced from 1.9% to 0.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DBV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DBV has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16.3% each year


Dividend

What is DBV Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DBV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DBV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DBV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DBV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DBV's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average management tenure


CEO

Daniel Tassé (61 yo)

3yrs

Tenure

US$2,062,135

Compensation

Mr. Daniel Tasse had been an Independent Non-Executive Director of Indivior PLC since August 2014 until May 6, 2021 and had been its Senior Independent Director since September 30, 2016 until May 6, 2021....


CEO Compensation Analysis

Compensation vs Market: Daniel's total compensation ($USD2.06M) is above average for companies of similar size in the French market ($USD511.56K).

Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: DBV's management team is considered experienced (2.5 years average tenure).


Board Members

Experienced Board: DBV's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

DBV Technologies S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: DBV Technologies S.A.
  • Ticker: DBV
  • Exchange: ENXTPA
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €291.378m
  • Shares outstanding: 54.96m
  • Website: https://www.dbv-technologies.com

Number of Employees


Location

  • DBV Technologies S.A.
  • 177-181 Avenue Pierre Brossolette
  • Montrouge
  • Ile-de-France
  • 92120
  • France

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/30 21:41
End of Day Share Price2021/11/30 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.